Other relevant information

PHARMA MAR, S.A.

• • 18/06/2020
  • 14:32
  • PHARMA MAR, S.A.
  • Other relevant information
  • The Board of Directors agrees to execute the reverse share split agreed by the General Shareholders’ Meeting.
  • Register number: 2862
• • 18/06/2020
  • 13:51
  • PHARMA MAR, S.A.
  • Other relevant information
  • The Company informs about the dividend payment
  • Register number: 2858
• • 18/06/2020
  • 13:40
  • PHARMA MAR, S.A.
  • Announcement of general shareholders’ meeting
  • It is reported that all proposed resolutions submitted by the Board to the General Shareholders’ Meeting have been approved.
  • Register number: 2855
• • 18/06/2020
  • 11:56
  • PHARMA MAR, S.A.
  • Announcement of general shareholders’ meeting
  • Attached is a copy of the presentation to shareholders to be made at the General Shareholders’ Meeting of Pharma Mar by the Chairman of the Company.
  • Register number: 2843
• • 17/06/2020
  • 17:35
  • PHARMA MAR, S.A.
  • Share buy-back , stabilisation and treasury stock programmes
  • The company reports the transactions performed in the context of the Share Buy-back Program between 10 June and 16 June 2020.
  • Register number: 2831
• • 10/06/2020
  • 17:36
  • PHARMA MAR, S.A.
  • Share buy-back , stabilisation and treasury stock programmes
  • The company reports the transactions performed in the context of the Share Buy-back Program between 3 June and 9 June 2020.
  • Register number: 2694
• • 08/06/2020
  • 17:39
  • PHARMA MAR, S.A.
  • Announcement of general shareholders’ meeting
  • The Company publishes a supplementary announcement regarding the call to the Annual General Shareholders’ Meeting
  • Register number: 2610
• • 03/06/2020
  • 17:47
  • PHARMA MAR, S.A.
  • Other relevant information
  • The Company reports that will host a virtual Key Opinion Leader (KOL) event on lurbinectedin and Small Cell Lung Cancer (SCLC) on June 10th, 2020, at 20.00 CET
  • Register number: 2554
• • 03/06/2020
  • 17:41
  • PHARMA MAR, S.A.
  • Share buy-back , stabilisation and treasury stock programmes
  • The company reports the transactions performed in the context of the Share Buy-back Program between 27 May and 2 June 2020.
  • Register number: 2553
• • 03/06/2020
  • 08:29
  • PHARMA MAR, S.A.
  • On business and financial situation
  • The Company announces that the Therapeutic Goods Administration (TGA) has granted the “Provisional Approval Pathway” for lurbinectedin in relapsed Small Cell Lung Cancer in Australia.
  • Register number: 2543